Industry
Biotechnology
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 1:14 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 8:15 pm
Portfolio Pulse from dijoy@benzinga.com
March 28, 2024 | 8:14 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 9:24 am
Portfolio Pulse from Benzinga Insights
March 27, 2024 | 3:02 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 12:24 pm
Portfolio Pulse from Benzinga Newsdesk
March 11, 2024 | 5:49 pm
Portfolio Pulse from Benzinga Newsdesk
March 05, 2024 | 1:52 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 1:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.